- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04044521
Promoting Clinical Guidelines for Opioid Prescribing
Promoting the Implementation of Clinical Guidelines for Opioid Prescribing in Primary Care Using Systems Consultation
Study Overview
Detailed Description
The proposed study evaluates a sequence and combination of implementation strategies that is tailored to the needs of stakeholders at different levels (health system, clinic, and prescriber). We will deliver an adaptive version of systems consultation that progressively and adaptively drills down to offer more and more personalized levels of implementation support. The intervention starts with academic detailing, a systems-level strategy consisting of an expert-led training session plus distance-based follow up support. This strategy continues for the 18-month intervention for all clinics, but at 3 months, half of the clinics will be randomized to receive practice facilitation. Practice facilitation is a clinic-level strategy in which a highly-skilled external change agent helps clinics improve processes related to opioid prescribing. At 6 months, half of prescribers will be randomized to receive physician peer coaching. Physician peer coaching is a clinic-level strategy in which a physician expert gives one-on-one support to prescribers in managing their patients on long-term opioid therapy. These 3 discrete strategies will be delivered in a sequential, multiple-assignment randomized trial to 38 clinics from 2 Wisconsin health systems. The study has 3 specific aims:
- Compare the effect over 18 months of (1). An adaptive systems consultation implementation strategy (intervention group) vs. (2). Academic detailing alone (control group) on average morphine milligram equivalent dose (the primary outcome).
- Develop an assessment of contextual factors that influence the effectiveness of different implementation strategies. This aim will test 4 moderators and assess other factors that affect implementation. The goal is to develop a tool that decision-makers can use to predict which implementation strategies will be most effective in different settings.
- Estimate the costs of delivering 4 different sequences and combinations of strategies, including the incremental cost effectiveness of adding facilitation and physician peer coaching. Results will help decision-makers weigh the costs and effects of using different implementation strategies.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54305
- Bellin Health Systems
-
Madison, Wisconsin, United States, 53792
- UW Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Clinics will be eligible for the study if they:
- are a primary care clinic (non-pediatric primary care, internal medicine, or family medicine);
- have not received the systems consultation intervention;
- do not explicitly prohibit initiating opioid therapy;
- do not exceed the performance on key measures of guideline concordance (fewer than 80% of long-term opioid patients have treatment agreements and a urine drug screen in the past 12 months)
Prescribers will be eligible if they:
- are a primary care provider at the clinic;
- are not temporary providers who do not manage stable panels or patients;
While patients are not subjects of study, de-identified prescriber panel data will be used to assess outcome measures. To be included in the de-identified prescriber panel data, patients must:
- have a primary care provider at the clinic;
- are prescribed opioid therapy for at least 3 consecutive months;
- do not have a cancer diagnosis or are receiving hospice care.
Exclusion Criteria:
Clinics will be excluded if they are not a primary care clinic, have received the systems consultation intervention, prohibit initiating opioid therapy, or exceed the threshold on key measures of guideline concordance.
Prescribers will be excluded if they don't have prescribing privileges or are temporary providers who do not manage stable panels or patients.
De-identified prescriber panel data will be excluded from outcome measures if they do not have a primary care provider at the clinic, are not prescribed opioid therapy for at least 3 consecutive months, or have a cancer diagnosis or are receiving hospice care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Academic detailing only
Clinicians will attend an educational meeting and receive audit and feedback reports for 18 months.
|
Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 18 months. AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit & feedback report on their prescribing. PF: clinics will be randomized to receive practice facilitation. Facilitators will travel to each clinics. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly. PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing. |
Experimental: Academic detailing+practice facilitation
Clinicians of this group will attend an educational meeting and receive a monthly audit and feedback report for 18 months. At month 3, clinics will be randomized to receive practice facilitation. Clinics will be asked to follow-up with the facilitators via phone or video chat monthly for months 4-6, then quarterly for months 7-18. |
Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 18 months. AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit & feedback report on their prescribing. PF: clinics will be randomized to receive practice facilitation. Facilitators will travel to each clinics. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly. PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing. |
Experimental: Academic detailing+practice facilitation+physician peer consul
Clinicians will receive academic detailing at month 0 and practice facilitation at month 3.
At month 6, clinics will be randomized to receive physician peer consulting.
Clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant.
|
Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 18 months. AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit & feedback report on their prescribing. PF: clinics will be randomized to receive practice facilitation. Facilitators will travel to each clinics. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly. PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing. |
Experimental: Academic detailing+physician peer consulting
Clinicians of this group will attend an educational meeting and will receive a monthly audit and feedback report for 18 months. At month 6, clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant. |
Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 18 months. AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit & feedback report on their prescribing. PF: clinics will be randomized to receive practice facilitation. Facilitators will travel to each clinics. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly. PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average morphine milligram equivalent (MME) of chronic opioid prescriptions of clinics
Time Frame: up to 30 months
|
The average morphine milligram equivalent will be reported at the clinic level. Patients included in this outcome are those who are prescribed at least 3 opioid orders in the last 3 consecutive months. For a comparison of opioids doses, a conversion factors were developed to equate the many different opioids into one standard value. This standard value is based on morphine and its potency, referred to as morphine milligram equivalents (MME) or morphine equivalent doses (MED). |
up to 30 months
|
Average morphine milligram equivalent of chronic opioid prescriptions of prescribers
Time Frame: up to 30 months
|
The average morphine milligram equivalent will be reported at the prescriber level.
Patients included in this outcome are those who are prescribed at least 3 opioid orders in the last 3 consecutive months.
|
up to 30 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients in a clinic who have chronic opioid prescriptions
Time Frame: up to 30 months
|
The number of patients who are prescribed at least 3 opioid orders in 3 consecutive months.
The number will be reported at the clinic level.
|
up to 30 months
|
Number of patients of a prescriber who have chronic opioid prescriptions
Time Frame: up to 30 months
|
The number of patients who are prescribed at least 3 opioid orders in 3 consecutive months.
The number will be reported at the prescriber level.
|
up to 30 months
|
Number of patients completing urine drug screens in the past 12 months
Time Frame: up to 30 months
|
Number of patients who are prescribed at least 3 opioid orders in 3 consecutive months, who have had a urine drug screen documented within the past 12 months.
|
up to 30 months
|
Number of patients completing screening for mental health and substance abuse within the past 12 months
Time Frame: up to 30 months
|
Number of patients who are prescribed at least 3 opioid orders in 3 consecutive months, who have a Patient Health Questionnaire (PHQ-9) documented within the past 12 months. The study team is not administering the screening tool, data will be provided by Wisconsin Collaborative for Healthcare Quality (WCHQ). The PHQ-9 is a 9-question instrument given to patients in a primary care setting to screen for the presence and severity of depression. It is the 9-question depression scale from the Patient Health Questionnaire. Total score can range from 1-27. Interpretation of total scores is as follows: 1-4=Minimal depression, 5-9=Mild depression, 10-14= Moderate depression, 15-19=Moderately severe depression, 20-27= Severe depression. |
up to 30 months
|
Number of patients who are co-prescribed opioids and benzodiazepines
Time Frame: up to 30 months
|
Number of patients who are prescribed at least 3 opioid orders in 3 consecutive months, who also have a concurrent benzodiazepine prescription.
|
up to 30 months
|
Average morphine milligram equivalent of patients who are co-prescribed opioids and benzodiazepines
Time Frame: up to 30 months
|
The average morphine milligram equivalent of patients who are prescribed at least 3 opioid orders in 3 consecutive months at the clinic level.
|
up to 30 months
|
Number of patients with treatment agreements within the past 12 months
Time Frame: up to 30 months
|
The number of patients who are prescribed at least 3 opioid orders in 3 consecutive months, who have documented treatment agreements within the past 12 months.
|
up to 30 months
|
Number of patients with a daily morphine milligram equivalent above 90 milligrams
Time Frame: up to 30 months
|
The number of patients who are prescribed at least 3 opioid orders in 3 consecutive months and have a daily morphine milligram equivalent over 90 milligrams.
|
up to 30 months
|
Number of emergency room visits and hospitalizations per patient
Time Frame: up to 30 months
|
The number of hospital or emergency room visits per patient among patients who are prescribed at least 3 opioid orders in 3 consecutive months.
|
up to 30 months
|
Number of patients who attend their scheduled clinic visits
Time Frame: up to 30 months
|
The number of patients who are prescribed at least 3 opioid orders in 3 consecutive months, who attend their scheduled clinic visits.
|
up to 30 months
|
Number of eligible clinics that participated
Time Frame: up to 30 months
|
The number of eligible clinics that participated in the study.
|
up to 30 months
|
Number of clinicians who participated in the study
Time Frame: up to 30 months
|
The number of eligible clinicians who participated in the study
|
up to 30 months
|
Number of clinicians who attended the intervention meetings
Time Frame: up to 30 months
|
The number of clinicians who attended the meeting for practice facilitation, physician peer consulting, and follow-up meetings.
|
up to 30 months
|
Average hours of intervention received per clinic
Time Frame: up to 30 months
|
The average time (in hours) of intervention that clinics received.
|
up to 30 months
|
Average hours of intervention received per prescriber
Time Frame: up to 30 months
|
The average time (in hours) of intervention that prescribers received.
|
up to 30 months
|
Number of adaptations made to the intervention during intervention period
Time Frame: up to 30 months
|
A list and count of adaptations that were made to the intervention during the intervention period will be documented.
|
up to 30 months
|
Cost of each study arm in US dollars
Time Frame: up to 30 months
|
The cost of each implementation sequence and combination in US dollars.
|
up to 30 months
|
Components of system-level opioid prescribing policy of the health systems
Time Frame: up to 30 months
|
A list and count of the components of the participating health systems' opioid prescribing policy.
|
up to 30 months
|
Quality improvement experience of the clinics
Time Frame: up to 30 months
|
A assessment tool is under development to capture the quality improvement experience level of clinics.
|
up to 30 months
|
Number of patients at clinics
Time Frame: up to 30 months
|
The total number of patients seen at clinics will be used to assess clinic size.
|
up to 30 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew Quanbeck, PhD, University of Wisconsin, Madison
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2018-1276
- A532007 (Other Identifier: UW Madison)
- SMPH/FAMILY MED/RES GRANTS (Other Identifier: UW Madison)
- R01DA047279 (U.S. NIH Grant/Contract)
- Protocol Version 8/31/2020 (Other Identifier: UW Madison)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use
-
Sharon WalshNational Institute on Drug Abuse (NIDA)Completed
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Indonesia UniversityRecruiting
-
Lawson Health Research InstituteNot yet recruiting
-
University of Colorado, DenverUniversity of Nebraska; Agency for Healthcare Research and Quality (AHRQ)Completed
-
Zulekha HospitalsCompleted
-
Peking University People's HospitalCompleted
-
University of UtahCompleted
-
University Health Network, TorontoOntario Ministry of Health and Long Term CareCompleted
Clinical Trials on Systems consultation
-
University College, LondonCompletedStroke | Auditory Processing Disorder, CentralUnited Kingdom
-
Centre Hospitalier Universitaire de NiceCompleted
-
University of Southern DenmarkUniversity of Copenhagen; University of Aarhus; Region North DenmarkCompletedQuality of Life | Life StyleDenmark
-
Vastra Gotaland RegionNot yet recruitingOsteoarthritis, Knee | Osteoarthritis, Hip
-
Universidade do PortoCompletedTrapezius Muscle StrainPortugal
-
University of Southern DenmarkOdense University Hospital; Sygekassernes Helsefond; Danish Nurses OrganisationCompleted
-
Boston Scientific CorporationRecruitingChronic PainUnited States, Spain, France, Germany, United Kingdom, Australia, Italy, Netherlands, Puerto Rico, Sweden, Switzerland
-
Osprey Medical, IncEnrolling by invitationPatients at Risk for Developing Contrast-induced NephropathyUnited States
-
NHS LothianUniversity of EdinburghTerminatedAbortion in First Trimester | Abortion EarlyUnited Kingdom
-
Hospital Israelita Albert EinsteinCompletedRespiratory Tract InfectionsBrazil